feed,title,long_url,short_url
MarketWatch,Intercept's stock plunges 35% premarket after receiving CRL from FDA for treatment of fibrosis due to NASH,http://feeds.marketwatch.com/~r/marketwatch/realtimeheadlines/~3/dh787ofUAtQ/quotes.asp,https://j.mp/2CL043G
